GD2TIF cells as a platform for single-dose and long-term delivery of biologics
The efficacy of biologics, such as peptide and protein drugs, is often limited by their short half-lives in vivo. GD2TIF cells expanded in immunocompetent mice without the need for chemotherapeutic conditioning and persisted as a polyclonal population, safely and almost indefinitely. Thus, GD2TIF cells be leveraged as a versatile platform for long-term delivery of biologics. In multiple disease models, GD2TIF cells were proved can be taken as a general platform for long-term delivery of biologics, offering durable therapeutic efficacy with a single infusion. Overall design: Splenic CD8+Thy1.1+ GD2TIF cells were sorted for scRNA-seq and TCR-seq at 2 months post transfer, for characterization of GD2TIF cells in a higher resolution.